Stories
Emcure Pharmaceuticals Approves Merger of Two Wholly-Owned Subsidiaries
N
News18•12-10-2026, 13:45
Emcure Pharmaceuticals Approves Merger of Two Wholly-Owned Subsidiaries
- •Emcure Pharmaceuticals Ltd board approved the merger of subsidiaries Zuventus Healthcare Ltd and Emcutix Biopharmaceuticals Ltd.
- •The amalgamation aims to achieve entity rationalisation and operational efficiency within the corporate group.
- •The implementation is subject to statutory and regulatory approvals, including the National Company Law Tribunal, Mumbai Bench.
- •No cash consideration will be paid and no new shares will be issued since both are wholly-owned subsidiaries.
- •Emcure Pharmaceuticals reported a turnover of Rs 5,243.19 crore for the financial year 2025-26.
Key Questions Answered
Emcure Pharmaceuticals approved the merger of its two wholly-owned subsidiaries, Zuventus Healthcare Ltd and Emcutix Biopharmaceuticals Ltd, with the holding company.
Because Zuventus Healthcare and Emcutix Biopharmaceuticals are wholly-owned subsidiaries, the scheme involves no cash consideration, no new share issuance, and no change to the listed entity's shareholding pattern.
The implementation of the amalgamation scheme is subject to required statutory and regulatory approvals under applicable laws, including a sanction from the National Company Law Tribunal, Mumbai Bench.
